CSF1 and hepatocellular carcinoma: In H22 and PDX mice model of HCC, PLX3397 further enhances CD8 T‐cell infiltration and activates intracellular immune responses by inhibiting the CSF1/CSF1R pathway in TAMs and reducing TAMs recruitment and M2 polarization, which is more effective and comprehensive to conquer sorafenib resistance in synergy with alleviating hypoxia.39